Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial - 27/05/14
, Annalisa Chiappella, MD a, Silvia Franceschetti, MD b, Angelo Michele Carella, MD c, Ileana Baldi, PhD d, Giorgio Inghirami, ProfMD e, g, Michele Spina, MD h, Vincenzo Pavone, MD i, Marco Ladetto, MD f, Anna Marina Liberati, ProfMD j, Anna Lia Molinari, MD k, Pierluigi Zinzani, ProfMD l, Flavia Salvi, MD m, Pier Paolo Fattori, MD n, Alfonso Zaccaria, MD o, Martin Dreyling, ProfMD p, Barbara Botto, MD a, Alessia Castellino, MD a, Angela Congiu, MD c, Marcello Gaudiano, PhD e, g, Manuela Zanni, MD f, Giovannino Ciccone, MD q, Gianluca Gaidano, ProfMD b, Giuseppe Rossi, MD ron behalf of the Fondazione Italiana Linfomi
Summary |
Background |
Up to 40% of elderly patients with untreated diffuse large B-cell lymphoma (DLBCL) given a regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP21) relapse or develop refractory disease. Lenalidomide has high activity in relapsed or refractory aggressive B-cell lymphomas. In phase 2 of the REAL07 trial, we aimed to establish the safety and efficacy of the combination of lenalidomide and R-CHOP21 in elderly patients with untreated DLBCL.
Methods |
REAL07 was an open-label, multicentre documents that was done in 13 centres in Italy and one in Germany. Eligible patients were aged 60–80 years; had newly diagnosed, untreated, CD20-positive, Ann Arbor stage II–IV DLBCL or grade 3b follicular lymphoma; had an Eastern Cooperative Oncology Group performance status of 0–2; had an International Prognostic Index (IPI) risk of low-intermediate, intermediate-high, or high; and were fit according to comprehensive geriatric assessment. Participants were to receive 15 mg oral lenalidomide on days 1–14 of six 21-day cycles, and standard doses of R-CHOP21 chemotherapy (375 mg/m2 intravenous rituximab, 750 mg/m2 intravenous cyclophosphamide, 50 mg/m2 intravenous doxorubicin, and 1·4 mg/m2 intravenous vincristine on day 1, and 40 mg/m2 oral prednisone on days 1–5). The primary endpoint was frequency of overall response (complete response [CR] and partial response [PR]), which was assessed by 18F-fluorodeoxyglucose (18F-FDG) PET at the end of the treatment. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00907348.
Findings |
49 patients were included in phase 2: nine had been enrolled into phase 1 between Oct 23, 2008, and June 4, 2009, and had received the maximum tolerated dose of 15 mg lenalidomide; and 40 were enrolled into phase 2 between April 28, 2010, and June 3, 2011. 45 patients (92%, 95% CI 81–97) achieved a response (42 [86%] CR; three [6%] PR). Three patients (6%) did not respond and one (2%) died for reasons unrelated to treatment or disease. 277 (94%) of 294 planned cycles of lenalidomide and R-CHOP21 were completed. Grade 3–4 neutropenia was reported in 87 cycles (31%), grade 3–4 leukopenia in 77 (28%), and grade 3–4 thrombocytopenia in 35 (13%). No grade 4 non-haematological adverse events were reported. No patients died during the study as a result of toxic effects.
Interpretation |
Lenalidomide with R-CHOP21 is effective and safe in elderly patients with untreated DLBCL.
Funding |
Fondazione Italiana Linfomi and Celgene.
Le texte complet de cet article est disponible en PDF.Plan
Vol 15 - N° 7
P. 730-737 - juin 2014 Retour au numéro
Article précédent
- Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study
- Nienke A de Glas, Willemien van de Water, Ellen G Engelhardt, Esther Bastiaannet, Anton J M de Craen, Judith R Kroep, Hein Putter, Anne M Stiggelbout, Nir I Weijl, Cornelis J H van de Velde, Johanneke E A Portielje, Gerrit-Jan Liefers
- Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
- Oliver Sartor, Robert Coleman, Sten Nilsson, Daniel Heinrich, Svein I Helle, Joe M O’Sullivan, Sophie D Fosså, Aleš Chodacki, Pawe? Wiechno, John Logue, Anders Widmark, Dag Clement Johannessen, Peter Hoskin, Nicholas D James, Arne Solberg, Isabel Syndikus, Nicholas J Vogelzang, C Gillies O’Bryan-Tear, Minghua Shan, Øyvind S Bruland, Christopher Parker
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?